Opinion statement
Initial empiric therapy for community-acquired bacterial meningitis should be based on the possibility that penicillin-resistant pneumococci may be the etiologic organisms and, hence, should include a combination of third-generation cephalosporin (cefotaxime or ceftriaxone) and vancomycin. Ampicillin should be included if the patient has predisposing factors that are associated with a risk for infection with Listeria monocytogenes. Bacterial isolates from the cerebrospinal fluid should be tested for antimicrobial susceptibility. Understanding the significance of inflammatory cytokines in the pathophysiology of bacterial meningitis leads to an understanding of the need to prevent their formation. Dexamethasone inhibits synthesis of the inflammatory cytokines, interleukin-1 and tumor necrosis factor. Results of clinical trials and meta-analysis suggest that dexamethasone therapy improves the outcome for patients with bacterial meningitis. Dexamethasone should be administered before or with the first dose of antibiotics. The development of therapeutic modalities to downregulate host inflammatory responses, such as those of monoclonal antibodies to cytokines, is of utmost importance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Vieusseux G: Memoire sur la maladie qui a regne a Geneve au printemps de 1805 (in French). J Med Chir Pharm 1806, 11:163–182.
Danielson L, Mann E: The history of a singular and very mortal disease which lately made its appearance in Medfield. In The Medical and Agricultural Register. Edited by Adams B. Boston: Manning and Loring; 1806:65–69.
Schwentker FF, Gelman S, Long PH: The treatment of meningococci meningitis with sulfanilamide. JAMA 1984, 251:788–790.
Scheld WM, Mandell GL: Sulfonamides and meningitis. JAMA 1984, 251:791–794.
Rosenberg DH, Arling PA: Penicillin in the treatment of meningitis. JAMA 1944, 125:1011–1017.
Tauber MG, Sande MA: The impact of penicillin on the treatment of meningitis. JAMA 1984, 251:1877–1880.
Schoendorf KC, Adams WG, Kiely JL, Wenger JD: National trends in Haemophilus influenzae meningitis mortality and hospitalization among children, 1980 through 1991. Pediatrics 1994, 93:663–668.
Klass PK, Klein JO: Therapy of bacterial sepsis and meningitis in infants and children: 1992 poll of directors of programs in pediatric infectious diseases. Pediatr Infect Dis J 1992, 11:702–705.
Pfister HW, Fontana A, Tauber MG, et al.: Mechanisms of brain injury in bacterial meningitis: workshop summary. Clin Infect Dis 1994, 19:463–479.
Frank M: Systemic and CNS toxicities of antimicrobial agents. In Central Nervous System Infectious Diseases and Therapy. Edited by Roos KL. New York: Marcel Dekker; 1987:711–730.
National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing. Villanova, PA: National Committee for Clinical Laboratory Standards; 1994.
John CC: Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 1994, 18:188–193.
Friedland IR, Paris M, Ehrett S, et al.: Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993, 34:231–237.
Klugman KP, Dagan R: Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis: Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995, 39:1140–1146.
Saez-Llorens X, Castano E, Garcia R, et al.: Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 1995, 39:937–940.
Mustafa MM, Ramilo O, Saez-Llorens X, et al.: Cerebrospinal fluid prostaglandins, interleukin-1 beta, and tumor necrosis factor in bacterial meningitis. Am J Dis Child 1990, 144:883–887.
Klugman KP, Friedland IR, Bradley JS: Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995, 39:1988–1992.
Lebel MH, Freij BJ, Syrogiannopoulos GA, et al.: Dexamethasone therapy for bacterial meningitis: results of two double blind, placebo controlled trials. N Engl J Med 1988, 319:964–971.
McIntyre PB, Berkey CS, King SM, et al.: Dexamethasone as adjunctive therapy in bacterial meningitis: a metaanalysis of randomized clinical trials since 1988. JAMA 1997, 278:925–931.
Odio CM, Zaglul C, Faingezicht I, et al.: A double-blind controlled study of 1 vs 4 days of dexamethasone for patients with purulent meningitis [abstract]. Proceedings of the American Society for Microbiology 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando: American Society for Microbiology; 1994:M30.
Syrogiannopoulos GA, Lourida AN, Theodoridou MC, et al.: Dexamethasone therapy for bacterial meningitis in children: 2-versus 4-day regimen. J Infect Dis 1994, 169:853–858.
Diringer MN, Kirsch JR: Disturbances of sodium and osmolality. In Current Therapy in Neurological Disease, edn 4. Edited by Johnson RT, Griffin JW. St. Louis: BC Decker; 1993:347–352.
Tureen JH, Tauber MG, Sande MA: Effect of hydration status on cerebral blood flow and cerebrospinal fluid lactic acidosis in rabbits with experimental meningitis. J Clin Invest 1992, 89:947–953.
Kaplan SL, Fishman MA: Supportive therapy for bacterial meningitis. Pediatr Infect Dis J 1987, 6:670–677.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roos, K.L. Bacterial meningitis. Curr Treat Options Neurol 1, 147–156 (1999). https://doi.org/10.1007/s11940-999-0014-8
Issue Date:
DOI: https://doi.org/10.1007/s11940-999-0014-8